SCIENTIFIC ARTICLES ON CANNABIS

Here you will find a list with hyperlinks to all the articles (full text or abstracts) online.

2018

Testing associations between cannabis use and subcortical volumes in two large population-based samples.

Gillespie, NA, et.al

Addiction. 2018 April 24 (abstract).

Enhancing the Therapeutic Efficacy of Cancer Treatment With Cannabinoids.

Yasmin-Karim, S, et. al

Frontiers in Oncology. 24 April 2018.

Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults A Systematic Review and Meta-analysis.

Scott, JC, et. al

JAMA Psychiatry. April 18, 2018.

Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population

Bradford, AC, et. al

JAMA Internal Medicine. Published online April 2, 2018 (abstract).

Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees

Wen, H, and Hockenberry, JM

JAMA Internal Medicine. Published online April 2, 2018 (abstract).

The Role of Cannabis Legalization in the Opioid Crisis.

Hill, KP, and Saxon, AJ

JAMA Internal Medicine. Published online April 2, 2018.

Effect of preprocessing high-resolution mass spectra on the pattern recognition of Cannabis, hemp, and liquor.

Wang, X, et.al

Talanta. Vol. 180, 1 April 2018, 229-238 (abstract).

Marijuana Use and Renal Function Among US Adults.

Chang Lu, BS, et. al

The American Journal of Medicine. April 2018, Vol. 131, Issue 4: 408–41 (abstract).

Cannabis and the Opioid Crisis.

Piomelli, D, et. al

Cannabis and Cannabinoid Research. Vol. 3, No.1, Roundtable Discussion, April 2018.

Marijuana use during and after pregnancy and association of prenatal use on birth outcomes: a population-based study*

Ko, JY, et. al

Drug and Alcohol Dependence. 2018 Mar 29, vol.187, 72-78 (abstract).

Cannabinoids for Treatment of Dystonia in Huntington’s Disease.

Saft, C, et al.

Journal of Huntington’s Disease. 2018 Mar 16 (abstract).

Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer.

Bar-Lev Schleider, L, et. al

European Journal of Internal Med.2018 Mar; 49:37-43.

Quantitative Determination of Δ9-THC, CBG, CBD, Their Acid Precursors and Five Other Neutral Cannabinoids by UHPLC-UV-MS.

Wang YH, et. al

Planta Medica. 2018 Mar; 84(04): 260-266 (abstract).

Marijuana use and fecundability in a North American preconception cohort study.

Wise LA, et.al

Journal of Epidemiology and Community Health. 2018 Mar;72(3):208-215 (abstract).

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

Thiele, EA, et. al

Lancet.2018 Mar 17;391(10125):1085-1096 (abstract).

Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.

Abuhasira, R, et. al

European Journal of Internal Medicine. 2018 Mar; 49:44-50 (abstract).

Crime and the legalization of recreational marijuana.

Dragone, D, et. al

Journal of Economic Behavior & Organization. 20 Feb 2018 (abstract).

Medical Cannabis for the Treatment of Fibromyalgia.

Habib, G, and Artul, S

Journal of Clinical Rheumatology. 2018 Feb 14.

Daily Cannabis and Reduced Risk of Steatosis in Human Immunodeficiency Virus and Hepatitis C Virus-co-infected Patients (ANRS CO13-HEPAVIH).

Nordmann, S, et. al

Journal of Viral Hepatitis. 2018 Feb; 25(2):171-179. Epub 2017 Nov 20 (abstract).

The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment

Gruber, SA, et. al

Frontiers in Pharmacology. Vol 8, article 983, 17 January 2018.

Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease.

Adejumo AC, et. al

Liver International. 2018 Jan 17 (abstract).

A prospective study of humoral and cellular immune responses to hepatitis B vaccination in habitual marijuana smokers.

Kiertscher SM, et. al

Journal of Neuroimmune Pharmacology. 2018 Jan 16 (abstract).

Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain.

Sohler NL, et. al

Substance Use and Misuse.2018 Jan 17:1-6 (abstract).

Marijuana use associations with pulmonary symptoms and function in tobacco smokers enrolled in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS).

Madeline A. Morris, et. al

Chronic Obstructive Pulmonary Disease. 2018; 5(1): 46-56.

2017

Marijuana use and renal function among US adults.

Lu C, et. al

American Journal of Medicine. 2017 Dec 29 (abstract).

Investigating the relationships between alcohol consumption, cannabis use and circulating cytokines: a preliminary analysis.

Karoly HC, et. al

Alcoholism Clinical and Experimental Research. 2017 Dec 29 (abstract).

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial.

McGuire P, et. al

American Journal of Psychiatry. 2017 Dec 15 (abstract).

Helping settle the marijuana and alcohol debate: evidence from scanner data.

Michele B, et.al

Social Science Research Network. 12 Dec 2017.

The effect of dronabinol in a male patient with anorexia nervosa suffering from severe acute urge to be physically active.

Graap H, et. al

International Journal of Eating Disorders. 2017 Dec 1(abstract).

HIV-infected cannabis users have lower circulating CD16+ monocytes and IP-10 levels compared to non-using HIV patients.

Rizzo MD, et al.

AIDS. 2017 Nov 30 (abstract).

Selective cannabinoid 2 receptor stimulation reduces tubular epithelial cell damage following renal ischemia-reperfusion injury.

Pressly JD, et. al

Journal of Pharmacology and Experimental Therapeutics. 2017 Nov 29 (abstract).

Cannabis use and hypomania in young people: a prospective analysis.

Marwaha S, et. al

Schizophrenia Bulletin. 2017 Nov 28 (abstract).

Lifetime marijuana use and subclinical atherosclerosis: the coronary artery risk development in young adults (CARDIA) study.

Auer R, et. al

Addiction. 2017 Nov 22 (abstract).

Is legal pot crippling Mexican drug trafficking organizations? The effect of medical marijuana laws on US crime.

Evelina Gavrilova, et. al

The Economic Journal, 16 Nov 2017 (abstract).

Cannabidiol (CBD) pre-review report agenda item 5.2 expert committee on drug dependence thirty-ninth meeting Geneva, 6-10 November 2017.

WHO, Expert Committee on Drug Dependence.

Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015.

Livingston MD, et. al

American Journal of Public Health. 2017 Nov; 107(11): 1827-1829 (abstract).

Crash fatality rates after recreational marijuana legalization in Washington and Colorado.

Aydelotte, Jayson D, et al.

American Journal of Public Health. 2017 June 22 (abstract).

The Health effects of cannabis and cannabinoids.

The current state of evidence and recommendations for research.

A report of the National Academies of Sciences – Engineering – Medicine.

The National Academies Press. 2017 Washington DC (book).

Cannabinoid CB2 receptors are involved in the protection of RAW264.7 macrophages against the oxidative stress; an in vitro study.

Giacoppo, Sabrina, et al.

European Journal of Histochemistry. 2017 61: 2749.

Cannabidiol modulates the expression of Alzheimer’s disease-related genes in mesenchymal stem cells.

Libro, Rosalina, et al.

International Journal of Molecular Sciences. 2017 18: 26.

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Jadoon, Khalid A, et al.

JCI Insight. June 2, 2017; 2(11): e93760.

The current status of artisanal cannabis for the treatment of epilepsy in The United States.

Sulak, Dustin, et al.

Epilepsy & Behavior. 2017 May 70 part B 328-333 (abstract).

Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial.

Cooper, RE, et al.

European Neuropsychopharmacology. May 30, 2017 (abstract).

Cannabis use and the course and outcome of major depressive disorder: a population based longitudinal study.

Feingold, D, et al.

Psychiatry Research. 2017 May 251: 225-234 (abstract).

Some of the Parts: is marijuana’s “entourage effect” scientifically valid?

Chen, Angus

Scientific American. 2017 April 20.

Marijuana use and serum testosterone concentrations among U.S. males.

Thistle, J E, et al.

Andrology. 2017 April 10 (abstract).

Cannabidiol reduces lung injury by hypoxic-ischemic brain damage in newborn piglets.

Arruza, L, et al.

Pediatric Research. 2017 April 7 (abstract).

Dual therapy targeting the endocannbinoid system prevents experimental diabetic nephropathy.

Barutta, F, et al.

Nephrology Dialysis Transplantation. 2017 April 6.

The impact of current cannabis use on general cognitive function in people with psychotic illness.

Waterreus, A, et al.

Schizophrenia Research. 2017 April 2 (abstract).

Medical marijuana policies and hospitalizations to marijuana and opioid pain reliever.

Shy, Y.

Drug and Alcohol Dependence. 2017 April 1 173: 144-150 (abstract).

Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.

Cremon, C, et al.

Alimentary Pharmacology & Therapeutics. 2017 April 45(7): 909-922 (abstract).

Cumulative lifetime marijuana use and incident cardiovascular disease in middle age: the coronary artery risk development in young (CARDIA) adults.

Reis, J P, et al.

American Journal of Public Health. 2017 April 107(4): 601-606 (abstract).

Development of a ?9-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability.

Adelli, Goutham, et al.

Investigative Ophthalmology & Visual Science. 2017 58:2167-2179.

Protective effects of cannabidiol against seizures and neuronal death in a rat model of mesial temporal.

Do Val-da Silva, Raquel A, et al.

Frontiers in Pharmacology. 2017 March 8: article 131.

Activation of CB1 receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary.

Karpi?ska, O, et al.

American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2017 March 29 (abstract).

Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial.

Naftali, T, et al.

Digestive Diseases and Sciences. 2017 March 27 (abstract).

Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor.

Guida, F, et al.

Scientific Reports. 2017 March 23, 7:375.

Improved social interaction, recognition and working memory with cannbidiol treatment in a prenatal infection (poly I:C) rat model.

Osborne, A L, et al.

Neuropsychopharmacology. 2017 March 22 (abstract).

Chronic pain patients perspectives of medical cannabis.

Piper, B J, et al.

Pain. 2017 March 21 (abstract).

Long lasting effects of chronic heavy cannabis abuse.

Nestoros, J N, et al.

American Journal of Addictions. 2017 March (abstract).

Cannabis use and bone mineral density: NHANES 2007-2010.

Bourne, Donald, et al.

Archives of Osteoporosis. 2017 March 12 29.

Cannabis use patterns and motives; a comparison of younger, middle aged, and older medical cannabis dispensary patients.

Haug, N A, et al.

Addictive Behaviors. 2017 March 9 72:14-20.

Palmitoylethanolamide reduces neuropsychiatric behaviors by restoring cortical electrophysiological activity in a mouse model of mild traumatic brain injury.

Guida, Francesca, et al.

Frontiers in Pharmacology. 2017 March 8: article 95.

Prolonged cannabis withdrawal in young adults with lifetime.

Schuster, R M, et al.

Preventive Medicine. 2017 Feb 27 (abstract).

Effects of tetrahydrocannabinol on glucose uptake in the rat brain.

Miederer, I, et al.

Neuropharmacology. 2017 Feb 20 117: 273-281 (abstract).

The inhibitory effect of S-777469, a cannabinoid type 2 receptor agonist, on skin inflammation in mice.

Haruna, T, et al.

Pharmacology. 2017 99(5); 259-267 (abstract).

Cannabidiol reduces ethanol, motivation and relapse in mice.

Viudez-Martinez, A, et al.

Addiction Biology. 2017 Feb 13 (abstract).

Bladder cancer cell growth and motility implicate cabbabinoid 2 receptor-mediated modifications of sphingolipids metabolism.

Bettiga, A, et al.

Scientific Reports. 2017 Feb 13 7: 42157.

Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis.

Pagano, E, et al.

Pharmacological Research. 2017 Feb 11 119:227-236 (abstract).

Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients.

Lucas, P, et al.

International Journal of Drug policy. 2017 Feb 9 42:30-35 (abstract).

Effects on spasticity and neuropathic pain of an oral formulation of ?9-tetrahydrocannabinol in patients with progressive multiple sclerosis.

van Amerongen, G, et al.

Clinical Therapeutics. 2017 Feb 9 (abstract).

Impact of cannabis use on treatment outcomes among adults receiving cognitive-behavioral treatment for PTSD and substance use disorders.

Ruglass, Lesia M, et al.

Journal of Clinical Medicine. 2017 Feb 7 6(2): 14-.

US traffic fatalities, 1985–2014, and their relationship to medical marijuana laws.

Santaella-Tenorio, J, et al.

American Journal of Public Health. 107, no. 2 (February 1, 2017): 336-342 (abstract).

Modulation of human peripheral blood mononuclear cell signaling by medicinal cannabinoids.

Utomo, Wesley, et al.

Frontiers in Molecular Neuroscience. 2017 January 10: article 14.

 β-Caryophyllene/hydroxypropyl-β-cyclodextrin inclusion complex improves cognitive deficits in rats with vascular dementia through the cannabinoid receptor type 2-mediated pathway.

Lou, Jie, et al.

Frontiers in Pharmacology.  2017 January 8: article 2.

(-)- β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis.

Alberti, Thaís Barbosa, et al.

International Journal of Molecular Sciences. 2017 18 691-.

Report from a survey of parents regarding the use of cannabidiol (medicinal cannabis) in Mexican children with refractory epilepsy.

Aguirre-Velázquez, Carlos G.

Neurology Research International. 2017 Article ID 2985729.

Cannabis as a substitute for opioid-based pain mediacation: patient self-report.

Reimann, Amanda, et al.

Cannabis and Cannabinoid Research. 2017 2 160-166.

Affinity and efficacy studies of tetrahydrocannabinolic acid A at cannabinoid receptor types one and two.

McPartland, John M, et al.

Cannabis and Cannabinoid Research. 2017 2 1 87-95.

Cannbinoids in Parkinson’s disease.

Stampanoni Bassi, Mario, et al.

Cannabis and Cannabinoid Research. 2017 2 1: 21-29.

Medical cannabis in the palliation of malignant wounds – a case report.

Maida, Vincent

Journal of Pain and Symptom Management. 2017 Jan 53(1): e4-e6.

Protective effects of trans-caryophyllene on maintaining osteoblast function.

Shan, J, et al.

IUBMB Life. 2017 Jan 69 (1): 22-19 (abstract).

2016

Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes.

Aizpurua-Olaizola O, et. al

Journal of Natural Products. 2016; 79:324–331.

Cannabis: From Cultivar to Chemovar II—A Metabolomics Approach to Cannabis Classification.

Arno Hazekamp, et.al

Cannabis and Cannabinoid Research. Volume 1.1, 202-215, 2016.

The combination of β-caryophyllene, baicalin and catechin synergistically suppresses the proliferation and promotes the death of RAW267.4 macrophages in vitro.

Yamaguchi, M, et al.

International Journal of Molecular Medicine.  2016 Dec 38(6): 1940-1946 (abstract).

Interactions between cannabidiol and ?9-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway.

Todd, S M, et al.

European Journal of Neuropsychopharmacology. 2016 Dec 30 (abstract).

URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy.

Wang, D, et al.

Neuroscience. 2016 Dec 30 (abstract).

Cannabis, tobacco, alcohol use, and the risk of early stroke: a population-based cohort study of 45 000 Swedish men.

Falkstedt, D, et al.

Stroke. 2016 Dec 27 (abstract).

Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.

Annunziata, P, et al.

Journal of Neuroimmunology.  2016 Dec 23 (abstract).

Mitochondrial functions of THP-1 monocytes following the exposure to selected natural compounds.

Schultze, N, et al.

Toxicology.  2016 Dec 21 377: 57-63 (abstract).

Cannabidiol reduce brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke.

Ceprián, M, et al.

Neuropharmacology. 2016 Dec 21, 116: 151-159 (abstract).

Synergistic attenuation of chronic pain mu opioid and cannabinoid receptor 2 agonists.

Grenald, S A, et al.

Neuropharmacology.  2016 Dec 20 116: 59-70 (abstract).

Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males.

Mokrysz, C, et. al

Translational Psychiatry. 2016 Nov 29.

Cannabinoid receptor 2 functional variant contributes to the risk for pediatric inflammatory bowel disease.

Strisciuglio, C, et al.

Journal of Clinical Gastroenterology. 2016 Nov 21 (abstract).

The cannabinoid beta-caryophyllene (BCP) induces neuritogenesis in PC12 cells by a cannabinoid-receptor-independent mechanism.

Santos, A, et al.

Chemico-Biological Interactions. 2016 Nov 18 261: 86-95 (abstract).

Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients.

Treat, L, et al.

Epilepsia. 2016 Nov 18 (abstract).

Prevalence and patterns of marijuana use in young adults with inflammatory bowel disease.

Phatak, U P, et al.

Journal of Pediatric Gastroenterology and Nutrition. 2016 Nov 14 (abstract).

The design of medical marijuana laws and adolescent use and heavy use of marijuana: analysis of 45 states from 1991-2011.

Johnson, J, et al.

Drug and Alcohol Dependence. 2016 Nov 4 170: 1-8 (abstract).

Efficacy and Safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized , double blind, placebo-controlled, parallel group pilot study.

Jadoon, K A, et al.

Diabetes Care. 2016 Oct 39(10): 1777-86 (abstract).

Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo.

Barbado, M V, et al.

International Journal of Cancer. 2016 Oct 25 (abstract).

Crystal structure of the human cannabinoid receptor CB1.

Hua, Tian, et al.

Cell. 2016 Oct 20 167: 750-762 (abstract).

Cannabinoids prevent the amyloid β-induced activation of astroglial hemichannels: A neuroprotective mechanism.

Gajardo-Gómez, R, et al.

Glia. 2016 Oct 19 (abstract).

Involvement of CB1 and TRPV1 and receptors located in the ventral medial prefrontal cortex in the modulation of stress coping behavior.

Sartim, A G, et al.

Neuroscience. 2016 Oct 19 (abstract).

Variants in the CNR1 gene predispose to headache with nausea in the presence of life stress.

Juhasz, G, et al.

Genes, Brain and Behavior. 2016 Oct 19 (abstract).

Cannabinoid receptor 2 activation restricts fibrosis and alleviates hydrocephalus after intraventricular hemorrhage.

Tan, Q, et al.

Brain Research. 2016Oct 18 (abstract).

Prevalence and correlates of “vaping” as a route of cannabis administration in medical cannabis patients.

Cranford, J A, et al.

Drug and Alcohol Dependence. 2016 Oct 15 169: 41-47 (abstract).

Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis.

Murillo-Rodriguez, E, et al.

Neuroscience. 2016 Oct 13 (abstract).

Medical cannabis and mental health; a guided systematic review.

Walsh, Z, et al.

Clinical Psychology Review 2016 Oct 12 51: 15-29 (abstract).

Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson’s disease.

Shohet, A, et al.

European Journal of Pain. 2016 Oct 10 (abstract).

Biovailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers.

Parikh, N, et al.

Clinical Pharmacology. 2016 Oct 12 8: 155-162.

Effectiveness of cannabidiol oil for pediatric anxiety and insomnia as part of posttraumatic stress disorder: a case report.

Shannon, S, et al.

The Permanente Journal.  2016 Oct 12 20(4) (abstract).

Splendor in the grass? A pilot study assessing the impact of medical marijuana on executive function.

Gruber, Staci A, et al.

Frontiers in Pharmacology. 2016 Oct 7: article 355.

An orally active cannabis extract with high content in cannabidiol attenuates chemically-induced intestinal inflammation and hypermotility in the mouse.

Pagano, Ester, et al.

Frontiers In Pharmacology. 2016 Oct 7: article 341.

Gingival stromal cells as an in vitro model: cannabidiol modulates genes linked with amyotrophic lateral sclerosis.

Soundara Rajan, T, et al.

Journal of Cellular Biochemistry. 2016 Oct 7 (abstract).

Marijuana Use and Estimated Glomerular Filtration Rate in Young Adults.

Ishida, JH, et. al

Clinical Journal of the American Society of Nephrology.Oct 06, 2017 vol. 12 no. 10: 1578-1587.

Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.

Vaia, M, et al.

European Journal of Pharmacology. 2016 Oct 5 791: 669-674 (abstract).

Beneficial effects of co-ultramicronized palmitoylethanolamide/luteolin in a mouse model of autism and in a case report of autism.

Bertolino, B, et al.

CNS Neuroscience & Therapeutics. 2016 Oct 4 (abstract).

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.

Hess, E J, et al.

Epilepsia. 2016 Oct 57(10): 1617-1624 (abstract).

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses.

Lawn, W, et. al

Psychopharmacology (Berl). 2016 Oct 233 (19-20):3537-52.

May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat.

Abalo, R, et al.

Neurogastroenterology & Motility. 2016 Sep 30 (abstract).

The effect of cannabinoids on dinitrofluorobenzene-induced experimental asthma in mice.

Bozkurt, T E, et al.

Respiratory Physiology & Neurobiology. 2016 Sep 231: 7-13 (abstract).

Cannabidiol prevents motor and cognitive impairments induced by reserpine in rats.

Peres, Fernanda, et al.

Frontiers in Pharmacology. 2016 Sep 28 7: article 343.

Neuroprotective effects of cannabidiol in hypoxic ischemic insult: the therapeutic window in newborn mice.

Mohammad, N, et al.

CNS & Neurological Disorders- Drug Targets. 2016 Sep 27 (abstract).

Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a regional pain syndrome type 1 in rats.

Xu, J, et al.

European Journal of Neurosciences. 2016 Sep 26 (abstract).

Got munchies? Estimating the relationship between marijuana use and body mass index.

Beulaygue, I C, et al.

Journal of Mental Health Policy and Economics. 2016 Sep 19(3): 123-140 (abstract).

An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease.

Wilsey, B, et al.

Journal of Pain. 2016 Sep 17(9): 982-1000 ( abstract).

Impact of cannabis, cannabinoids and endocannabinoids in the lungs.

Turcotte, Caroline, et al.

Frontiers in Pharmacology. 2016 Sep 15 7: article 317.

Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure.

De Sousa Fernandes Perna, E B, et al.

Psychopharmacology. 2016 Sep, vol. 233, Issue 18, 3331-3340.

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats.

Brierly, D I, et al.

Psychopharmacology (Berl). 2016 Aug (abstract).

Spontaneous cannabinoid receptor 2 (CB2) expression in the cochlea of adult albino rat and its up-regulation after cisplatin treatment.

Martin-Saldaña, S, et al.

PLoS One. 2016 Aug 26 11(8).

Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy.

Szczesniak, A M, et al.

Neuropharmacology. 2016 Aug 25 (abstract).

Marijuana use in adults admitted to a Canadian epilepsy monitoring unit.

Massot-Tarrús, A, et al.

Epilepsy Behavior. 2016 Aug 25 (abstract).

Severe motor and vocal tics controlled with Sativex®.

Trainor, D, et al.

Australasian Psychiatry. 2016 Aug 24 (abstract).

Testing longitudinal relationships between binge drinking, marijuana use, and depressive symptoms and moderation by sex.

Wilkinson, A L, et al.

Journal Adolescent Health. 2016 Aug 23 (abstract).

Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study.

Schoeler, Tabea, et al.

Lancet Psychiatry. 2016 August 22.

Cannabinoid type 1 receptor antagonism ameliorates harmaline-induced essential tremor in rat.

Abbassian H, et al.

British Journal of Pharmacology. 2016 Aug 21 (abstract).

Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer

MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness.

Takeda, S, et al.

Journal of Natural Medicines. 2016 Aug.16 (abstract).

Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model.

Aso, E, et al.

Journal of Alzheimer’s Disease. 2106 Aug 10 (abstract).

The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats.

Suleymanova, E M, et al.

Neuroscience. 2016 Aug 9. (abstract).

Sex-dependent effects of cannabis-induced analgesia.

Cooper, Z D, et al.

Drug and Alcohol Dependence. 2016 Aug 5 (abstract).

Pure ?9-tetrahydrocannabivarin and a cannabis sativa extract with high content in ?9-tetra-hydrocannabivarin inhibit production in murine peritoneal macrophages.

Romano, B, et al.

Pharmacological Research. 2016 Aug.3 (abstract).

Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson’s disease.

Javed, Hayate, et al.

Frontiers in Neuroscience. 2016 August 2 10: article 321.

Effective treatment of spasticity using dronabinol in pediatric palliative care.

Kuhlen, M, et al.

European Journal of Paediatric Neurology. 2016 July 30 (abstract).

The availability of medical marijuana dispensary and adolescent marijuana use.

Shi, Y

Preventive Medicine. 2016 July 25 91: 1-7 (abstract).

Medical marijuana laws reduce prescription medication use in medicare part D.

Bradford, A C, et al.

Health Alf (Millwood). 2016 July 1 35(7): 1230-1236 (abstract).

Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids.

Currais, Antonio, et al.

NPJ Aging and Mechanisms of Disease 2. 2016 June 23.

Prenatal cannabis and tobacco exposure in relation to brain morphology: a prospective neuroimaging study in young children.

El Marroun, H, et al.

Biological Psychiatry. 2016 June 15 179(12): 971-979 (abstract).

Indirect modulation of the endocannabinoid system by specific fractions of nutmeg total extract.

El-Alfy, Abir T, et al.

Pharmaceutical Biology. 2016 June 13.

Opioid and cannabinoid synergy in a mouse neuropathic pain model.

Kazantzis, N P, et al.

British Journal of Pharmacology. 2016 June 9 (abstract).

Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood.

Sagar, Kelly, et al.

PLOS One. 2016 June 8.

Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.

Patel, R R, et al.

Brain. 2016 June 5 (abstract).

Pharmacological activation of cannabinoid 2 receptor attenuates inflammation, fibrogenesis, and promotes re-epithelialization during skin wound healing.

Wang, L L, et al.

European Journal of Pharmacology. 2016 June 3 786: 128-136 (abstract).

Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a case series.

Trigo, J M, et al.

Journal of Addiction Medicine. 2016 June 3 (abstract).

Marijuana use and its effects in pregnancy.

Chabarria, K C, et al.

American Journal of Obstetrics and Gynecology. June 2 (abstract).

Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose.

Zaurova, M, et al.

Journal of Medical Toxicology.2016 June 2 (abstract).

The derivation of modern cannabis varieties.

Rahn, Bailey, et al.

Critical Reviews in Plant Sciences. 2016 35(5/6): Cannabis.

Medicinal uses of marijuana and cannabinoids.

Grotenhermen, Franjo, et al.

Critical Reviews in Plant Sciences. 2016 35(5/6): Cannabis.

Associations between cannabis use and physical health problems in early midlife: a longitudinal comparison of persistent cannabis vs tobacco users.

Meier, M H, et al.

JAMA Psychiatry. 2016 June 1 (abstract).

Effects of medical marijuana on migraine headache frequency in an adult population.

Rhyne, D N, et al.

Pharmacotherapy. 2016 May 36(5): 505-510 (abstract).

Pain, cannabis species and cannabis use disorders.

Cohen, N L, et al.

Journal of studies on alcohol and drugs. 2016 May 77(3): 515-520 (abstract).

TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer.

Elbaz, Mohamad, et al.

Oncotarget. 2016 May 27.

I use weed for my ADHD: a qualitative analysis of online forum discussions on cannabis use and ADHD.

Mitchell, John T, et al.

PLOS ONE. 2016 May 26.

Grey matter changes associated with heavy cannabis use; a longitudinal sMRI study.

Koenders, Laura, et al.

PLOS One. 2016 May 25.

Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial.

Andresen, S R, et al.

Pain. 2016 May 25 (abstract).

Marijuana use is not associated with progression to advanced liver fibrosis in HIV/HCV coinfected women.

Kelly, E M, et al.

Clinical and Infectious Diseases. 2016 May 25 (abstract).

Effects of delta-9-tetrahydrocannabinol and cannabidiol on cisplatin-induced neuropathy in mice.

Harris, Hannah M, et al.

Planta Medica. 2016 May 23 82: 1169-1172.

Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease.

Manuel, I, et al.

Neuroscience. 2016 May 17 329: 284-293 (abstract).

Influence of previous failed antispasticity therapy on the efficacy and tolerability of THC:CBD oromucosal spray for multiple sclerosis spasticity.

Haupts, M, et al.

European Neurology. 2016 May 10 75(5-6): 236-243 (abstract).

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti, F, et al.

Journal of Neurology Neurosurgery and Psychiatry. 2016 May 9.

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease.

López-Sendón Moreno, J L, et al.

Journal of Neurology. 2016 May 9 (abstract).

Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors

produce antipruritic effect in mice.

Yesilyurt, O, et al.

Archives of Dermatological Research. 2016 April 28 (abstract).

Evaluating the effects of gamma-irradiation for decontamination of medicinal cannabis.

Hazekamp, Arno

Frontiers in Pharmacology. 2016 April 27 7: article 108.

Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice.

Sonego, A B, et al.

Behavioural Brain Research. 2016 April 27 309: 22-28 (abstract).

Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrheic skin and acne treatment.

Oláh, A, et al.

Experimental Dermatology. 2016 April 20 (abstract).

No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells

in HIV-HCV co-infected patients (ANRS CO-HEPAVIH French cohort).

Marcellin, F, et al.

Drug and Alcohol Review. 2016 April 13 (abstract).

Cannabidiol promotes browning in 3T3-L-1 adipocytes.

Parray, H A, et al.

Molecular and Cellular Biochemistry. 2016 April 11 (abstract).

Cannabis and cannabinoids (PDQ®). Health professional version.

PDQ Integrative, alternative and complementary therapies editorial board.

Published online. 2016 April 8.

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical

5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

Linge, R, et al.

Neuropharmacology. 2016 April 103: 16-26 (abstract).

1169-021 / 21-Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction.

Poster presentation American College of Cardiology 2016 Scientific Sessions.

2016 April 3 (abstract).

Cannabis and cannabinoids (PDQ®). Patient version.

PDQ integrative, alternative and complementary editorial board.

Published online. 2016 April 1.

Effects of fixed or self-titrated dosages of Savitex on cannabis withdrawal and cravings.

Trigo, J M, et al.

Drug and Alcohol Dependence. 2016 April 1 161: 298-306 (abstract).

The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.

Marinelli, L, et al.

International Journal of Clinical Psychopharmacology. 2016 Mar. 21 (abstract).

Cannabis and cancer: toward a new understanding.

Ware, M A

Current Oncology. 2016 23 Suppl.2: S5-S6.

Why I chose to use cannabis.

Perrier, L

Current Oncology. 2016 23 Suppl.2: S7.

Integrating cannabis into clinical cancer care.

Abrams, D I

Current Oncology. 2016 23 Suppl.2: S8-S14.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Fischer, T, et al.

Current Oncology. 2016 23 Suppl.2: S15-S22.

Anticancer mechanisms of cannabinoids.

Velasco, G, et al.

Current Oncology. 2016 23 Suppl.2: S23-32.

Use of cannabinoids in cancer care: palliative care.

Aggarwal, S K

Current Oncology. 2016 23 Suppl. 2: S33-S36.

Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis.

Gunn, J K L, et al.

BMJ Open. 2016 6(4).

Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients..

Boehnke, K F, et al.

Journal of Pain. 2016 Mar. 18 (abstract).

Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease.

Köfalvi, A, et al.

Neuropharmacology. 2016 Mar. 11 (abstract).

Prevalence of marijuana use does not differentially increase among youth after states pass medical marijuana laws: commentary on and reanalysis of US National Survey on drug use in households data 2002-2011.

Wall, M M, et al.

International Journal of Drug Policy. 2016 Mar. 29:9-13 (abstract).

Prohedonic effect of cannabidiol in a rat model of depression.

Shoval, G, et al.

Neuropsychobiology.2016 73(2): 123-129 (abstract).

Metabolic syndrome in people with a psychotic illness: is cannabis protective?

Waterreus, A, et al.

Psychological Medicine.2016 Mar. 11: 1-12 (abstract).

Effects of cannabinoid receptor activation by CP55,940 on normal bladder function and irritation-induced bladder overactivity in non-awake anaesthetised rats.

Bakali, E, et al.

International Urogynecology Journal. 2016 Mar. 4 (abstract).

A single intrathecal or intraperitoneal injection of CB2 receptor agonist attenuates bone cancer pain and induces a time-dependent modifaction of GRK2.

Lu, C, et al.

Cellular and Molecular Neurobiology. 2016 Mar. 2 (abstract).

Combined treatment with morphine and ?9-tetrahydrocannibinol (THC) in rhesus monkeys:

antinociceptive tolerance and withdrawal.

Gerak, L R, et al.

Journal of Pharmacology and Experimental Therapeutics. 2016 Mar. 2 (abstract).

An event-related potential study on the effects of cannabis on emotion processing.

Troup, Lucy J, et al.

PLOS ONE. 2016 Feb. 29.

Use of cannabis during pregnancy and birth outcomes in an aboriginal birth cohort: a cross-sectional, population-based study.

Brown, S J, et al.

BMJ Open. 2016 Feb. 23.

CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience.

Tzadok, M, et al.

Seizure.2016 Feb. 35: 41-44 (abstract).

Anti-inflammatory and osteoprotective effects of cannabinoid-2 receptor agonist Hu-308 in a rat model of lipopolysaccharide-induced periodontitis.

Ossala, C A, et al.

Journal of Periodontology. 2016 Feb. 5:1-17 (abstract).

Adverse effects of cannabis on adolescent brain development: a longitudinal study.

Camchong, J, et al.

Cerebral Cortex. 2016 Feb. 23 (abstract).

Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study.

Mokrysz, C, et. al

Journal of Psychopharmacology. 2016 Feb 30(2): 159-168.

Health authorities data collection of THC:CBD (Sativex) oromucosal spray (L’Agenzia Italiana del farmaco web registry): figures after 1.5 years.

Patti, Francesco

European Neurology. 2016 75(suppl.1): 9-12.

THC:CBD (Sativex) observational study data: evolution of resistant MS spasticity and associated symptoms.

Trojano, Maria

European Neurology. 2016 75(suppl.1): 4-8.

THC:CBD (Sativex) in daily practice: available data from UK, Germany and Spain.

Fernández, Oscar

European Neurology. 2016 75(suppl.1): 1-3.

Fatty acid amide hydrolase inhibitors anti-invasive and antimetastatic effects on lung cancer cells,

Winkler, K, et al.

Oncotarget. 2016 Feb. 22 (abstract).

Cannabis effects on driving longitudinal control with and without alcohol.

Hartman, R L, et al.

Journal of Applied Toxicology. 2016 Feb.18 (abstract).

The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-y and CB2 pathways.

Del Rio, C, et al.

Scientific Report. 2016 Feb. 18 6:21703 (abstract).

Cannabis effects on driving longitudinal control with and without alcohol.

Hartman, R L, et al.

Journal of Applied Toxicology. 2016 Feb. 18 (abstract).

The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study.

Haroutounian, S, et al.

Clinical Journal of Pain. 2016 Feb. 17 (abstract).

Stimulation of cannabinoid CB1 receptors prevents nerve-mediated airway hyperreactivity in NGF-induced inflammation in mouse airways.

Bozkurt, T E, et al.

European Journal of Pharmacology. 2016 Feb. 16 (abstract).

Meta-analysis of the association between the level of cannabis use and risk of psychosis.

Marconi, A, et al.

Schizophrinia Bulletin. 2016 Feb.15 (abstract).

Endocannabinoid concentrations in hair are associated with PTSD symptom severity.

Wilker, S, et al.

Psychoneuroendocrinology. 2016 Feb. 12 67: 198-206 (abstract).

Cannabis and psychosis: a critical overview of the relationship.

Ksir, C, et al.

Current Psychiatry Reports. 2016 Feb. 18(2): 12 (abstract).

A study of the impact of cannabis on doses of discharge antipsychotic medication in individuals with schizophrenia or schizoaffective disorder.

Babatope, T, et al.

Psychiatric Quarterly. 2016 Feb. 13 (abstract).

Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice.

Frei, R B, et al.

Allergy. 2016 Feb.  6 (abstract).

Marijuana use patterns and sleep among community-based young adults.

Conroy, D A, et al.

Journal of Addiction Disorders. 2016 35(2): 135-43 (abstract).

Prior cannabis use is associated with outcome after intracerebral hemorrhage.

Di Napoli, M, et al.

Cerebrovascular Diseases. 2016 Jan. 29 41(5/6): 248-255 (abstract).

Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119).

Helle, S, et al.

Schizophrenia Research. 2016 Jan. 170(1): 217-221 (abstract).

Prior cannabis use is associated with outcome after intracerebral hemorrhage.

Di Napoli, M, et al.

Cerebrovascular Disease. 2016 Jan. 29 41(5-6): 248-255 (abstract).

Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies.

Jackson, NJ, et. al

Proceedings of the National Academy of Sciences.  January 19, 2016.

The cannabis sativa versus cannabis indica debate; an interview with Ethan Russo, MD.

Piomelli, Danielle, et al.

Cannabis and Cannabinoid Research. 2016 1(1): 44-46.

Review on clinical studies with cannabis and cannabinoids 2010-2014.

Kowal, Mikael A, et al.

Cannabinoids. 2016 11(special issue): 1-18.

Cannabis use, depression and anxiety: a 3-year prospective population-based study.

Danielsson, Anna-Karin, et al.

Journal of Affective Disorders. 2016 193: 103-108.

Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model.

Nam, Gaewon, et al.

Annals of Dermatology. 2016 28(1): 22-29.

Training and practices of cannabis dispensary staff.

Haug, Nancy A, et al.

Cannabis and Cannabinoid Research. 2016 1 1: 244-251.

Seventh European workshop on cannabinoid research and IACM eighth conference on cannabinoids in medicine.

Cheer, Joseph F, et al.

Cannabis and Cannabinoid Research. 2016 1 1: 54-58.

Medicinal Cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis.

Lanz, Christian, et al.

PLOS ONE. 2016 January.

Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies.

Jackson, N J, et al.

Proceedings of the National Academy of Sciences U S A. 2016 Jan. 19 (abstract).

Expression of cannabinoid receptors in human osteoarthritic cartilage: implications for future therapies.

Dunn, Sara L, et al.

Cannabis and Cannabinoid Research. Vol. 1, Issue 1, Jan. 14, 2016.

Evaluating Sativex in neuropathic pain management; a clinical and neurophysiological assessment in multiple sclerosis.

Russo, Margherita, et al.

Pain Medicine. 2016 January 13.

Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: an-open label, add-on, pilot study.

Shelef, A, et al.

Journal of Alzheimers Disease. 2016 Jan. 12 (abstract).

Effects of medical marijuana on migraine headache frequency in an adult population.

Rhyne, D N, et al.

Pharmacotherapy.  2016 Jan.  9 (abstract).

Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation.

Lee, W S, et al.

Molecular Medicine. 2016 Jan. 8 (abstract).

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.

Kozela, Ewa, et al.

Journal of Neuroinflammation. 2016 13: 136.

Preliminary development of a brief cannabis use disorder screening tool: the cannabis use disorder identification test short-form.

Bonn-Miller, Marcel O, et al.

Cannabis and Cannabinoid Research. 2016 1(1): 252-261.

Dronabinol has preferential antileukemic activity in acute lymphoid differentiation patterns.

Kampa-Schittenhelm, Kerstin Maria, et al.

BMC Cancer. 2016 16:25.

2015

Development and Validation of a Reliable and Robust Method for the Analysis of Cannabinoids and Terpenes in Cannabis.

Giese, M, et al.

Journal of AOAC International. Vol. 98, No. 6, 2015, 1503-1522.

The association between cannabis use and anxiety disorders: results from a population-based representative sample.

Feingold, D, et al.

European Neuropsychopharmacology. 2015 Dec. 29 (abstract).

Differences in cannabis-related experiences between patients with a first episode of psychosis and controls.

Bianconi, F, et al.

Psycological Medicine. 2015 Dec. 16 1-9 (abstract).

Therapy with a selective cannabinoid receptor type 2 agonist limits albuminuria and renal injury in mice with type 2 diabetic nephropathy.

Zoja, C, et al.

Nephron. 2015 Dec. 9 (abstract).

Pharmaceutical CBD (cannabidiol) shows promise for children with severe epilepsy.

Significant seizure reduction in studies using CBD in combination with AEDs.

American Epilepsy Society.

Science Daily. 2015 Dec. 7.

Head and neck cancer among marijuana users; a meta-analysis of matched case-control studies.

de Carvalho, M F, et al.

Archives of oral Biology. 2015 Dec. 60(12): 1750-1755 (abstract).

Prevention of diet-induced obesity effects on body weight and gut microbiota in mice treated chronically with ?9-tetrahydrocannabinol.

Cluny, Nina L, et al.

PLOS One 2015 December 3.

Long-term data of efficacy, safety and tolerability in a real life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients.

Paolicelli, D, et al.

Journal of clinical Pharmacology. 2015 Nov. 26 (abstract).

Cannabis liberalization and adolescent cannabis use: a cross-national study in 38 countries.

Shi, Yuyan, et al.

PLOS One 2015 November 25.

Controlled release tablet formulation containing natural 9 tetrahydrocannabinol.

Punyamurthula, N S, et al.

Drug Development and Industrial Pharmacy. 2015 Nov. 20: 1-25 (abstract).

Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice.

Verty, A N A

Plos One. 2015 November 20.

The effects of five day dosing with THCV in THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial.

Englund, A, et al.

Journal of Psychopharmacology. 2015 Nov. 17 (abstract).

Anti-inflammatory effects of N-acylethanolamines in rheumatoid arthritis synovial cells are mediated by TRPV1 and TRPA1 in a COX-2 dependent manner.

Lowin, Torsten, et al.

Arthritis Research & Therapy. 2015 Nov. 14 17: 321.

Interaction between cannabis consumption and childhood abuse in psychotic disorders: preliminary findings on the role of different patterns of cannabis use.

Sideli, L, et al.

Early Intervention in Psychiatry. 2015 Nov. 12 (abstract).

Pharmacological benefits of selective modulation of cannabinoid receptor type 2 (CB2) in experimental Alzheimer’s disease.

Jayant, S, et al.

Pharmacological Biochemical Behavior. 2015 Nov. 11 (abstract).

Heavy cannabis users at elevated risk of stroke: evidence from a general population survey.

Hemachandra, D, et al.

Australian and New Zealand Journal of Public Health. 2015 Nov. 11 (abstract).

Overview of CBC

Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Nov. 11.

Cannabinoid receptor type 1 agonist ACEA improves recovery and protects neurons in ischemic stroke in mice.

Caltana, L, et al.

Journal of Neurochemistry. 2015 Nov. 135(3): 616-629 (abstract).

Metabolic syndrome among marijuana users in the United States: an analysis of national health and nutrition examination survey data.

Vidot, D C, et al.

American Journal of Medicine. 2015 Nov. 5 (abstract).

Perinatal asphyxia results in altered expression of the hippocampal acylethanolamide/ endocannabinoid signaling system associated to memory impairments in postweaned rats.

Blanco, Eduardo, et al.

Frontiers in Neuroanatomy. 2015 November 3.

Substituting cannabis for prescription drugs, alcohol and other substance among medical cannabis patients: the impact of contextual factors.

Lucas, Philippe, et al.

Drug and Alcohol Review. 2015 (abstract).

Cannabis species and cannabinoid concentration among sleep-disturbed medicinal cannabis users.

Belendiuk, Katherine A, et al.

Addictive Behaviors. 2015 November 50: 176-181 (abstract).

No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk.

Loflin, Mallory, et al.

Canadian Journal of Respiratory Therapy. 2015 51(1): 7-9.

The disease-modifying effects of Savitex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to ?(9)-tetrahydrocannabinol acting through CB1 receptors.

Moreno-Martet, M, et al.

Multiple Sclerosis and Related Disorders. 2015 Nov. 4(6) 505-511 (abstract).

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model arthritis.

Hammell, D C, et al.

European Journal of Pain. 2015 Oct. 30 (abstract).

Cannabidiol, a major non-psychotropic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts.

Kogan, N M, et al.

Journal of Bone and Mineral research. 2015 Oct 30 (10) 1905-1913 (abstract).

Overview of CBN.

Medicinal value of cannabinol (CBN)-Medical Marijuana Inc. 2015 Oct.29.

Endocannabinoid signaling in autism.

Chakrabarti, Bhismadev et al.

Neurotherapeutics. 2015 Oct 12(4): 837-847.

Finding cannabinoids in hair does not prove cannabis consumption.

Moosmann, Bjoern et al.

Nature Scientific Reports. 2015 October 7.

Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers.

Haney, M, et al.

Neuropsychopharmacology.2015 Oct. 40(11): 2489-2498 (abstract).

A runner’s high depends on cannabinoid receptors in mice.

Fuss, J, et al.

Proceedings of the National Academy of Sciences USA. 2015 112(42): 13105-8 (absract).

Adult attention deficit hyperactivity symptoms and psychosis: epidemiological evidence from a population survey in England.

Marwaha, S, et al.

Psychiatry Research. 2015 Sep. 30, 229(1-2): 49-56 (abstract).

Relationship between cannabis and psychosis: reasons for use and associated clinical variables.

Mané, A, et al.

Psychiatry Research. 2015 Sep. 30, 229(1-2): 70-74 (abstract).

Association between marijuana use and adverse obstetrical and neonatal outcomes.

Warshalk, C R, et al.

Journal of Perinatology. 2015 Sep. 24 (abstract).

Cannabis.

Grayson, Michelle.

Nature Supplement. 2015 September 24, 525 No. 750_supp ppS1-S18.

Actions of the dual FAAH/MAGL inhibitor JZL 195 in a murine neuropathic pain model.

Adamson Barnes, N S, et al.

British Journal of Pharmacology. 2015 Sep. 23 (abstract).

Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys.

Maguire, D R, et al.

Behavioural Pharmacology. 2015 Sep. 21 (abstract).

Neural correlates of cannabidiol and ?9-tetrahydrocannabinol interactions in mice: implications for medical cannabis.

Todd, S M, et al.

British journal of Pharmacology. 2015 Sep.17 (abstract).

Cannabis for the management of pain: assessment of safety study (COMPASS).

Ware, M A, et al.

Journal of Pain. 2015 Sep. 16 (see separate binder).

Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis.

Weiss, A, et al.

Drug and Alcohol Dependence. 2015 Sep. 14 (abstract).

Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors.

Lucas, P, et al.

Drug and Alcohol Review. 2015 Sep. 14 (abstract).

The CB1 neutral antagonist tetrahydrocannabivarin reduces default mode network and increases executive control network resting state functional connectivity in healthy volunteers.

Rzepa, Ewelina, et al.

International Journal of Neuropsychopharmacology. 2015 Sep 14, 1-7.

Potential therapeutic value of a novel FAAH inhibitor for the treatment of anxiety.

Marco, Eva M, et al.

PLOS One. 2015 September 11.

Endocannabinoid modulation of predator stress-induced long-term anxiety in rats.

Lim, J, et al.

Neuropsychopharmacology. 2015 Sep. 11 (abstract).

Anadamide mediates cognitive judgement bias in rats.

Kregiel, J, et al.

Neuropsychopharmacology. 2015 Sep. 9 (abstract).

The effect of medical marijuana laws on body weight.

Sabia, Joseph J, et al.

Health Economics 2015 September 8.

Divergent marijuana trajectories among men: socioeconomic, relationship, and life satisfaction outcomes in the mid-30s.

White, H R, et al.

Drug and Alcohol Dependence. 2015 Sep. 5 (abstract).

Bone cell-autonomous contribution of type 2 cannabinoid receptor to breast cancer induced osteolysis.

Sophocleous, Antonia, et al.

Journal of Biological Chemistry. 2015 Sep. 4 290(36): 22049-60.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga, A, et al.

Drug and Alcohol Dependence. 2015 Sep. 1 154: 38-45 (abstract).

The genetic structure of marijuana and hemp.

Sawler, Jason, et al.

PLOS One. 2015 Aug. 26.

Shared predisposition in the association between cannabis use and subcortical brain structure.

Pagliaccio, David, et al.

JAMA Psychiatry 2015 August 26.

Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice.

Schmitz, K, et al.

International Journal of Obesity. 2015 Aug.  25 (abstract).

Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol.

Ho, W S, et al.

British Journal of Pharmacology. 2015 Aug.  21 (abstract).

Sativex ® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Leocani, L, et al.

Journal of Neurology. 2015 Aug.  20 (abstract).

Association between use of marijuana and male reproductive hormones and semen quality: a study among 1,215 healthy young men.

Gundersen, T D, et al.

American of Epidemiology. 2015, 182(6): 473-481.

Endocannabinoid regulation of amyloid-induced neuroinflammation.

Vàzquez, C, et al.

Neurobiology of Aging. 2015 Aug. 15 (abstract).

Cannabidiol, a cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release.

Gobira, P H, et al.

Neurotoxicology. 2015 Aug. 15 (abstract).

Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide prospective, register-based study.

Hjorthøj, C, et al.

Lancet Psychiatry. 2015 Aug. 12 (abstract).

Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis.

Arnold, C, et al.

Schizophrenia Research. Aug. 7 (abstract).

Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men.

Bechtold, J, et al.

Psychology of Addictive Behaviors. 2015 Aug. 3 (abstract).

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease.

Mounsey, R B, et al.

Experimental Neurology. Aug. 2 273: 36-44 (abstract).

Use and effects of cannabinoids in military veterans with posttraumatic stress disorder.

Betthauser, Kevin, et al.

American Journal of Health-System Pharmacy. 2015 August 72: 1279-1284.

No additive effect of cannabis on cognition in schizophrenia.

Power, B D, et al.

Schizophrenia Research. 2015 July 30 (abstract).

Brief report: cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples.

Alshaarawy, O, et al.

Epidemiology. 2015 July 26 (4): 597-600 (abstract).

Natural outcome of cannabis use disorder: a three-year longitudinal follow-up.

Feingold, D, et al.

Addiction. 2015 July 25 (abstract).

Analysis of the anti-allodynic effects of combination of a synthetic cannabinoid and a selective noradrenaline re-uptake inhibitor in nerve injury-induced neuropathic mice.

Gunduz, O, et al.

European Journal of Pain. 2015 July 24 (abstract).

Novel triazolopyrimidine-derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases.

Nettekoven, M, et al.

ChemMedChem.2015 July 21 (abstract).

Notes from the field: death following ingestion of an edible marijuana product – Colorado, March 2014.

Hancock-Allen, Jessica B, et al.

Morbidity and Mortality Weekly Report. 2015 July 24 64(28): 771-772.

Time-dependent protection of CB2 receptor agonist in stroke.

Yu, Seong-Jin, et al.

PLOS One. 2015 July 17 10(7).

Activation of CB2 receptor is required for the therapeutic of ABHD6 inhibition in experimental autoimmune encephalomyelitis.

Wen, J, et al.

Neuropharmacology. 2015 July 17 99: 196-209 (abstract).

Cannabis allergy: what do we know anno 2015.

Decuyper, I, et al.

Archivum Immunologiae et Therapiae Experimentalis. 2015 July 16 (abstract).

Enhanced vasorelaxation of endogenous anandamide on thoracic aorta in renal vascular hypertension rats.

Guo, Z, et al.

Clinical and Experimental Pharmacology and Physiology. 2015 July 14 (abstract).

Cannabinoids and terpenes as chemotaxonomic markers in cannabis.

Elzinga, S, et al.

Natural Products Chemistry & Research. 2015 3(4): 181.

The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.

Bisaga, A, et al.

Drug and Alcohol Dependence. 2015 July 8 (abstract).

Nonsmoker exposure to secondhand cannabis smoke. III. Oral fluid and blood drug concentrations and corresponding subjective effects.

Cone, E J, et al.

Journal of Analytical Toxicology. 2015 July 2 (abstract).

Cannabis use and reduced risk of insulin resistance analysis (ANRS CO13 HEPAVIH).

Carrieri, Maria Patrizia, et al.

Clinical Infectious Diseases. 2015 July 1 61.

Cannabis in cancer care.

Abrams, Donald I, et al.

Clinical Pharmacology & Therapeutics. 2015 June 97(6): 575-586.

Medical marijuana for treatment of chronic pain and other medical and psychiatric problems.

A clinical review.

Hill, Kevin P

JAMA. 2015 313 June 23/30 (24): 2474-2483.

Are cannabidiol and 9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland, John M, et al.

British Journal of Pharmacology. 2015 172: 737-753.

Cannabis sativa: the unconventional “weed” allergen.

Ocampo, Thad L, et al.

Annals of Allergy, Asthma & Immunology. 2015 114: 187-92

Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors.

Shakoor, S, et al.

Psychiatry Research. 2015 June 30 227(2/3): 144-51 (abstract).

Cannabinoid dose and label accuracy in edible medical cannabis products.

Vandrey, Ryan, et al.

JAMA. 2015 June 23/30 313(24): 2491-2493.

Medical marijuana. Is the cart before the horse.

D’Souza, Deepak Cyril, et al.

JAMA. 2015 June 23/30 313(24): 2431-2432.

Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users.

Gilman, Jodi M, et al.

The Journal of Neuroscience. 2015 June 28 35(4): 1505-1512.

Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation.

Stanley, C P, et al.

Cardiovascular Research. 2015 June 19 (abstract).

Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 1994:

results from annual, repeated cross-sectional surveys.

Hasin, Deborah S, et al.

The Lancet (psychiatry). 2015 June 16.

Cannabinoids for the treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials.

Lynch, M E, et al.

Journal of Neuroimmune Pharmacology. 2015 June 10 (2): 293-301 (abstract).

Pharmacologic effects of cannabidiol on acute reperfused myocardial infarction in rabbits: evaluated with 3.OT cardiac magnetic resonance imaging and histopathology.

Feng, Y, et al.

Journal of Cardiovascular Research. 2015 June 9 (abstract).

Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial.

van den Elsen, G A, et al.

Neurology. 2015 June 9 84(23): 2338-2346 (abstract).

Synergy between cannabidiol, cannabidiolic acid, and ?9-tetrahydrocannabinol in the regulation of emesis in the Suncus murinus (house musk shrew).

Rock, E M, et al.

Behavioral Neuroscience. 2015 June 129 (3): 368-70 (abstract).

Cannabinoids for medical use: a systematic review and meta-analysis.

Whiting, Penny F, et al.

JAMA. 2015 313(24): 2456-2473.

Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol.

Hartman, Rebecca L, et al.

Clinical Chemistry. 2015 61(6): 850-869.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Presley, Chaela, et al.

Pharmacology, Research & Perspectives. 2015 3(4): 1-16.

Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it’s been…..

Baron, E P

Headache. 2015 May 25 (abstract).

Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Fu W, et al.

Neuroscience Letters. 2015 May 19 595:1-6 (abstract).

Cannabis smoking and diabetes mellitus: results from meta-analysis with eight independent replication samples.

Alshaarawy, O, et al.

Epidemiology. 2015 May 14 (abstract).

CB1 receptors modulate affective behaviour induced by neuropathic pain.

Rácz, I, et al.

Brain Research Bulletin. 2015 May 114: 42-48 (abstract).

Use of prescription pain medications among medical cannabis patients: comparison of pain levels, functioning, and patterns of alcohol and other drug use.

Perron, Brian E, et al.

Journal of Studies on Alcohol and Drugs. 2015 May 76(3): 406-418.

The antitumor activity of plant-derived non-psychoactive cannabinoids.

McAllister, Sean D, et al.

Journal of Neuroimmune Pharmacology. 2015 April.

Differential role of cannabinoids in the pathogenesis of skin cancer.

Glodde, N, et al.

Life Sciences. 2015 April 25 (abstract).

A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.

Felilú, A, at al.

British Journal of Pharmacology. 2015 April 8 (abstract).

Current status and future of cannabis research.

Russo, Ethan B, et al.

Clinical Researcher. 2015 April 58.

Introduction to the endocannabinoid system.

Russo, Ethan

Phytex Website. 2015.

Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado.

Finseth, Taylor Andrew, et al.

Evidence Based Complementary and Alternative Medicine. 2015 article ID 874849.

Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder.

Kvitland, Levi Roestad, et al.

BMC Psychiatry. 2015 15: 11.

Phytocannabinoids and epilepsy.

dos Santos, R G, et al.

Journal of Clinical Pharmacy and Therapeutics. 2015 April 40(2): 135-143.

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation In Parkinson’s disease.

Gòmez-Gálvez, Y, et al.

Progress in Neuropsychopharmacology & Biological Psychiatry. 2015 April 9 (abstract).

Efficacy of inhaled cannabis on painful diabetic neuropathy.

Wallace, M S, et al.

Journal of Pain. 2015 April 2 (abstract).

Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.

Press, C A, et al.

Epilepsy & Behavior. 2015 April 2 (abstract).

Medical marijuana for cancer.

Kramer, Joan L.

CA A Cancer Journal for Clinicians. 2015 March/April 65(2): 109-122.

Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men.

Bechtold, Jordan, et al.

Psychology of Addictive Behaviors. 2015 29(3): 552-563.

No smoke, no fire: what the initial literature suggests regarding vapourized cannabis and respiratory risk.

Loflin, Mallory, et al.

Canadian Journal of Respiratory Therapy. 2015 51(1): 7-9.

The therapeutic potential of cannabinoids for movement disorders.

Kluger, Benzi, et al.

Movement Disorders.2015 30(3): 313-327.

Cannabidiol, a major non-psychotrophic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts.

Kogan, N M, et al.

Journal of Bone and Mineral Research. 2015 March 19 (abstract).

Exploiting cannabinoid-induced cytotoxic autophagy to drive melanoma cell death.

Armstong, Jane L, et al.

Journal of Investigative Dermatology. 2015 March 12 135: 1629-1637.

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Di Forti, Marta, et al.

The Lancet Psychiatry. 2015 March 2(3): 233-238.

Cannabis use in relation to obesity and insulin resistance in the Inuit population.

Ngueta, Gerard et al.

Obesity. 2015 February 23(2).

Medical marijuana for digestive disorders: high time to prescribe?

Gerich, Mark E, et al.

The American Journal of Gastroenterology. 2015 February 110: 208-214.

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia.

Ahmed, Amir I A, et al.

Psychopharmacology. 2015 232: 2587-2595.

Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study.

van der Meer, F J, et al.

Psychological Medicine. 2015 Feb. 5:1-12 (abstract).

Cannabis use in relation to obesity and insulin resistance in the Inuit population.

Ngueta, G, et al.

Obesity. 2015 Feb. 23 (2): 290-295 (abstract).

Selective nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.

Morales, P, et al.

Journal of Medicinal Chemistry. 2015 Feb. 20 (abstract).

Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa.

Monteleone, A M, et al.

American Journal of Clinical Nutrition. 2015 Feb. 101(2): 262-269 (abstract).

Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol.

Gallily, Ruth, et al.

Pharmacology & Pharmacy. 2015 Feb.10, 6: 75-85.

Association between cannabis use and the risk of bladder cancer: results from the California men’s health study.

Thomas, A A, et al.

Urology. 2015 Feb. 85(2): 388-393 (abstract).

Synthetic and natural cannabinoids: the cardiovascular risk.

Russo, Ethan B

The British Journal of Cardiology. 2015 22(1) January-March: 7-9.

Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.

Lachenmeier, Dirk W, et al.

Scientific Reports. 2015 Jan. 30.

Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice.

Rahimi, A, et al.

Neuroscience. 2015 Jan.28: 290C: 279-287 (abstract).

Daily marijuana use is not associated with brain morphometric measures in adolescents or adults.

Weiland, Barbara, J, et al.

The Journal of Neuroscience. 2015 January 28 35(4): 1505-1512.

Proapoptotic effect of endocannabinoids in prostate cancer cells.

Orellana-Serradell, O, et al.

Oncology Reports. 2015 Jan. 21.

Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Feng, R, et al.

Molecular Carcinogenesis. 2015 Jan. 16 (abstract).

The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study.

Jetly, R, et al.

Psychoneuroendocrinology. 2015 Jan. 15, 51: 585-588 (abstract).

Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis.

Silvestri, C, et al.

Journal of Hepatology. 2015 Jan. 13 (abstract).

Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria.

de Campos, A C, et al.

Neuroscience. 2015 Jan. 13 (abstract).

Arachidonoyl-ethanolamide activates endoplasmic reticulum stress-apoptosis in tumorigenic keratinocytes: role of cyclooxcygenase-2 and novel J-series prostamides.

Soliman, E, et al.

Molecular Carcinogenesis. 2015 Jan. 3 (abstract).

The conversation and transfer of cannabinoids from cannabis to smoke stream in cigarettes.

Elzinga, Sytze, et al.

Natural Products and Chemistry Research. 2015 3 (1).

Medical cannabis healthcare provider info.

Sulak, D.

Healer.com 2015.

Cannabis shopping guide.

Sulak, D.

Healer.com. 2015.

2014

Handbook of Cannabis

Pertwee, Roger (ed.)

Oxford University Press. 2014 (see separate book).

The combination of cannabidiol and ?9-tetrahydrocannabinol enhances murine glioma model.

Scott, Katherine A, et al.

Molecular Cancer Therapeutics. 2014 13(12): 2955-2967.

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model.

Greco, Rosaria, et al.

The Journal of Headache and Pain. 2014, 15:14.

Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis.

Gui, H, et al.

Immunobiology. 2014 Dec.30 (abstract).

Medical marijuana laws and suicides by gender and age.

Anderson, DM, et al.

American Journal of Public Health. 2014 Dec. 104(12): 2369-2376 (abstract).

Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions.

Jenkin, KA, et al.

Clinical and Experimental Pharmacology & Physiology. 2014 Dec. 29 (abstract).

Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin (THCv) on food reward and aversion in healthy volunteers.

Tudge, L, et al.

International Journal of Neuropsychopharmacology. 2014 Dec.25.

Involvement of central and peripheral receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.

Bagüés, A, et al.

European Journal of Pharmacology. 2014 Dec. 15, 745:69-75 (abstract).

Chronic Stimulation of the tone of endogenous anandamide reduces cue-and stress-induced relapse in rats.

Chauvet, C, et al.

International Journal of Neuropsychopharmacology. 2014 Dec.5.

Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the pain and opioids in treatment (POINT) study.

Degenhardt, L, et al.

Drug Alcohol Dependence. 2014 Dec. 10 (abstract).

Effects of marijuana exposure on expiratory airflow: a study of adults who participated in the U.S. national health and nutrition examination study.

Kempker, JA, et al.

Annals of the American Thoracic Society. 2014 Dec. 18 (abstract).

Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration.

Silveira, JW, et al.

PLoS One. 2014 Dec. 17 9(12).

The combination of cannabidiol and ?9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model.

Scott, Katherine A, et al.

Molecular Cancer Therapeutics. 2014 Dec. 13 (12): 2955-67 (abstract).

Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury.

Zhang, J, et al.

Journal of Cerebral Blood Flow & Metabolism. 2014 Dec. 10 (abstract).

Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice.

Neelakantan, H, et al.

Behavioral Pharmacology. 2014 Dec. 5 (abstract).

Gross morphological brain changes with chronic, heavy cannabis use.

Lorenzetti, V, et al.

British Journal of Psychiatry. 2014 Nov. 27 (abstract).

?9 Tetrahydrocannabinol attenuates staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells.

Rao, R, et al.

British Journal of Pharmacology. 2014 Nov. 26 (abstract).

Early phytocannabinoid chemistry to endocannabinoids and beyond.

Mechoulam, Raphael, et al.

Nature Reviews/Neuroscience 2014 Nov. 15: 757-764.

Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.

Viana, TG, et al.

Psychopharmacology(Berl.). 2014 Nov. 13 (abstract).

High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load recently infected people who use injection drugs.

Milloy, MJ, et al.

Drug Alcohol Review. 2014 Nov. 11 (abstract).

Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Zhang, Hai-Ying, et al.

Proceedings of the National Academy of Sciences. 2014 Nov. 3 E5007-E5015.

Effect of marijuana use on outcomes in traumatic brain injury.

Nguyen, B M, et al.

American Journal of Surgery. 2014 Oct. 80(10): 979-83 (abstract).

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.

Sexton, M, et al.

Inflammopharmacology. 2014 Oct, 22(5): 295-303 (abstract).

The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival attenuates inflammation and improves functional recovery in mice with traumatic brain injury.

Tchantchou, F, et al.

Neuropharmacology. 2014, Oct. 85: 427-39 (abstract).

Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.

Cameron, C, et al.

Journal of Clinical Psychopharmacology. 2014 Oct, 34(5): 559-564.

Legalization of medical marijuana and incidence of opioid mortality.

Hayes, Marie J, et al.

JAMA Internal Medicine. 2014, 174(10): 1673-1674 (abstract).

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid.

Borrelli, F, et al.

Carcinogenesis. 2014 Sep. 30 (abstract).

Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors.

Pietrzak, Robert H, et al.

Neuropsychopharmacoloy. 2014, 39:2519-2528 (abstract).

Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage.

Smith, P H, et al.

Psychology of Addictive Behaviors. 2014 Sep, 28(3): 734-742 (abstract).

Cannabidiol improves vasorelaxation in Zucker Diabetic fatty rats through cyclooxygenase activation.

Wheal, A J, et al.

Journal of Pharmacology and Experimental Therapeutics. 2014 Sep. 11 (abstract).

Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability.

Freidel, M, et al.

Acta Neurologica Scandinavica. 2014 Sep. 11.

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).

Salaga, M, et al.

Journal of Chronic Colitis. 2014 Sep 1, 8(9): 998-1009.

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

Bachhuber, M A, et al.

JAMA Internal Medicine. 2014 Aug. 25 (abstract).

Preliminary, open-label, pilot study of add-on oral ?9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

Roitman, P, et al.

Clinical Drug Investigation. 2014 Aug, 34(8): 587-591 (abstract).

β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 mice through CB2 receptor activation and the PPARy pathway.

Cheng, Y, et al.

Pharmacology. 2014 Aug, 94(1-2): 1-12 (abstract).

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.

Aso, E, et al.

Journal of Alzheimers Disease. 2014, Aug. 14 (abstract).

Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1Δ E9 Mice.

Cheng, D, et al.

Psychopharmacology. 2014 Aug, 231(15): 3009-3017 (abstract).

Cannabionoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Haustein, M, et al.

Biochemical Pharmacology. 2014 Jul. 25, 15:92 (abstract).

The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study.

Giordano, G N, et al.

Psychological Medicine. 2014 Jul. 3: 1-8 (abstract).

The impact of cannabis use on clinical outcomes in recent onset psychosis.

Barrowclough, C, et al.

Schizophrenia Bulletin. 2014 July 9 (abstract).

Does the legalization of medical marijuana increase completed suicide?

Rylander, M, et al.

The American Journal of Drug and Alcohol Abuse. 2014 Jul, 40(4): 269-273.

The comprehensive report on the cannabis extract movement and the use of cannabis extracts to treat diseases.

Kander, Justin

5th edition 2014 July (separate binder).

Genetic predisposition to schizophrenia associated with increased use of cannabis.

Power, R A, et al.

Molecular Psychiatry. 2014 19: 1201-1204.

Cannabis smoking and lung cancer risk: pooled analysis in the international lung cancer consortium.

Zhang, L R, et al.

International Journal of Cancer. 2014 Jun 30.

Type-1 cannabinoid receptor activity during Alzheimer’s disease progression.

Manuel, I, et al.

Journal of Alzheimers Disease. 2014 Jun 19, 42(3): 761-766 (abstract).

Genetic predisposition to schizophrenia associated with increased use of cannabis.

Power, R A, et al.

Molecular Psychiatry. 2014 Jun 24, EISSN: 1476-5578 (abstract).

Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.

Flachenecker, P, et al.

European Neurology. 2014 Jun 18, 72(1-2): 95-102 (abstract).

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience.

Waissengrin, B, et al.

Journal of Pain Symptom Management. 2014 Jun 14, pii: S0885-3924(14)00312-1 (abstract).

β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice.

Bahi, A, et al.

Physiology & Behavior. 2014 Jun 13, 135C: 119-124 (abstract).

Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors.

Grassin-Delyle, S, et al.

British Journal of Pharmacology. 2014 Jun, 171(11): 2767-2777 (abstract).

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series.

Chagas, M H, et al.

Journal of Clinical Pharmacy and Therapeutics. 2014 May 21, 2014 Oct, 39(5): 564-566 (abstract).

Cannabis and cannabinoids (PDQ). health professional version.

National Cancer Institute. May 13 2014.

Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity.

Castelli, Paola M, et al.

PLoS One. 2014: 9(5): e98079.

Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis.

Buchy, L, et al.

Schizophrenia Research. 2014 May, 156(2-3): 277-280 (abstract).

Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American Academy of Neurology.

Koppel, Barbara S, et al.

Neurology. 2014 April 29: 1556-1563.

The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.

Klauke, A L, et al.

European Neuropsychopharmacology. 2014 Apr, 24(4): 608-620 (abstract).

Evaluation of selective of cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. 

Tambaro, S, et al.

European Journal of Pharmacology. 2014 Apr 15, 729: 67-74 (abstract).

Fasting and exercise increase plasma cannabinoid levels in THC pretreated rats: an examination of behavioural consequences.

Wong, A, et al.

Psychopharmacology. 2014 Apr 3 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of parkinson disease: an open-label observational study.

Lotan, I, et al.

Clinical Neuropharmacology. 2014 Mar-Apr, 37(2): 41-44 (abstract).

Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias.

Rodriguez-Cueto, C, et al.

Pathobiology. 2014 Mar 14, 81(3): 49-159 (abstract).

Anandamide inhibits breast tumor-induced angiogenesis.

Picardi, P, et al.

Translational Medicine. 2014, 10(3): 8-12.

Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use.

Loflin, Mallory, et al.

Substance Use & Misuse. 2014 Mar, 49(4): 427-434 (abstract).

Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration.

Lax, Pedro, et al.

Experimental Eye Research. 2014 Mar, 120: 175-185 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson’s disease: an open-label observational study.

Lotan, I, et al.

Clinical Neuropharmacology. 2014 Mar, 37(2): 41-44 (abstract).

Care and feeding of the endocannabinoid system: A systematic review of potential interventions that upregulate the endocannabinoid system.

McPartland, John M, et al.

PLOS One. 2014 Mar, 9(3): 1-21.

That which we call Indica, by any other name would smell as sweet.

Erkelens, Jacob L, et al.

Cannabinoids. 2014, 9(1): 9-15.

Nabiximols (THC/CBD oromucosal spray, sativex in clinical practice-results of a multicenter, non-interventional study (move2) in patients with multiple sclerosis spasticity.

Flachenecker, P, et al.

European Neurology. 2014, 71(5-6): 271-279 (abstract).

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.

Florek-Luszczki, Magdalena, et al.

Journal of Neural Transmission. 2014 Feb 19, 121(7): 707-715.

Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice.

Schiavon, A P, et al.

Neurotoxicity Research. 2014 Feb 15 (abstract).

Cannabidiol as a potential treatment for psychosis.

Schubart, C D, et al.

European Neuropsychopharmacology. 2014 Jan, 24(1): 51-64 (abstract).

Emerging clinical applications for cannabis and cannabinoids. A review of the recent scientific literature. Sixth Edition.

Armentano, Paul

The National Organization for the Reform of Marijuana Laws. Jan 13 2014: 1-69 (see separate binder).

Cannabis in neurology-a potted review.

Hosking, Richard, et al.

Nature Reviews Neurology. 2014 10: 429-430.

Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model.

Harvey, B S, et al.

Cytokine. 2014 Feb, 65(2): 236-244 (abstract).

Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy.

Ward, S J, et al.

British Journal of Pharmacology. 2014 Feb, 171(3): 636-645.

A controlled family study of cannabis users with and without psychosis.

Proal, A C, et al.

Schizophrenia Research. 2014 Jan, 152(1): 283-288 (abstract).

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Smith, S C, et al.

Neuro Endocrinology Letters. 2014 35(3): 198-201 (abstract).

2013

Cannabis inflorescence, Cannabis spp. Standards of identity, analysis, and quality control.

Upton, Roy, et al.

American Herbal Pharmacopoeia. 2013 Dec, (see separate binder).

The endocannabinoid system and emotional processing: a pharmacological fMRI study with Δ9-tetrahydrocannabinol.

Bossong, Matthijs G, et al.

European Neuropsychopharmacology. 2013 Dec, 23(12): 1687-1697.

Marijuana use patterns among patients with inflammatory bowel disease. 

Ravikoff Allegretti, Jessica, et al.

Inflammatory Bowel Diseases.  2013 Dec, 19(13): 2809-2814.

Impact of ADHD and cannabis use on executive functioning in young adults.

Tamm, Leanne, et al.

Drug and Alcohol Dependence. 2013 December 1 133(2).

Cannabidivarin (CBDV) suppresses penthylenetretrazole (PTZ)-induced increases in epilepsy-related gene expression.

Amada, Naoki, et al.

Peer Journal. 2013 Nov 21, 1: e214.

Risk of road-accident associated with the use of drugs: a systematic review and meta-analysis of

evidence from epidemiological studies.

Elvik, R

Accident Analysis and Prevention. 2013 Nov. 60:254-267 (abstract).

Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.

Scott, K A, et al.

Anticancer Research. 2013 Oct, 33(10): 4373-4380 (abstract).

Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat.

Calik, M W, et al.

Respiratory Physiology & Neurobiology. 2013 Oct, 190: 20-24.

Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study.

Naftali, Timna, et al.

Clinical Gastroenterology and Hepatology. 2013 Oct, 11(10): 1276-1280 (abstract).

Cannabinoids alter endothelial function in the Zucker rat model of type 2 diabetes.

Stanley, C P, et al.

European Journal of Pharmacology. 2013 Oct 8, 720(1-3): 376-382 (abstract).

Sub-types of attention deficit-hyperactivity disorder (ADHD) and cannabis use.

Loflin, M, et al.

Substance Use & Misuse. 2013 Oct 4, 49(4): 427-434 (abstract).

Marijuana: current concepts.

Greydanus, Donald E, et al.

Frontiers in Public Health 2013 October Article 42.

Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.

Cooper, Z D, et al.

Neuropsychopharmacology. 2013 Sep, 38(10): 1984-1992.

Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis.

Brunet, Laurence, et al.

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2013 Sep 1, 57(5): 663-670.

Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings.

Morgan, C J, et al.

Addiction Behaviors. 2013 Sep, 38(9): 2433-2436 (abstract).

Elevated brain cannabinoid CB1 receptor availability in posttraumatic stress disorder: a positron emission tomography study.

Neumeister, Alexander, et al.

Molecular Psychiatry. 2013 Sep, 18(9): 1034-1040.

Comparison of the analgesic effects of Dronabinol and smoked marijuana in daily marijuana smokers.

Cooper, Z D, et al.

Neuropsychopharmacology. 2013 Sep, 38(10): 1984-1992.

Why pot makes you feel good.

Cholewa, K M, et al.

AlterNet.org. 2013 Aug 18, online article.

The medicinal use of cannabis and cannabinoids – an international cross-sectional survey on administration forms.

Hazekamp, A, et al.

Journal of Psychoactive Drugs. 2013 Jul-Aug, 45(3): 199-210 (abstract).

The medical necessity for medicinal cannabis: prospective, observational study evaluating the treatment in cancer patients supportive for palliative care. 

Bar-Sela, Gil, et al.

Evidence-based Complementary and Alternative Medicine. 2013, e510392.

An ultra-low dose of tetrahydrocannabinol provides cardioprotection.

Waldman, M, et al.

Biochemical Pharmacology. 2013 Jun 1, 85(11): 1626-1633 (abstract).

Effects of marijuana smoking on the lung.

Annals of the American Thoracic Society. 2013 Jun, 10(3): 239-247.

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

Wargent, E T, et al.

Nutrition and Diabetes. 2013 May 27, 3, e68.

Talking terpenes.

Lee, Martin, A

High Times. May 2013.

THC can prevent brain damage – study.

Science 2.0, 2013 May 30.

Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception.

Katsuyama, S, et al.

European Journal of Pain. 2013 May 17(5): 664-675 (abstract).

High on health: cannabinoids in the food supply.

Badiner, Alan

www.wakingtimes.com. 2013 Apr 25.

Cannabinergic pain medicine: a concise primer and survey of randomized-controlled trial results.

Aggarwal, S K

Clinical Journal of Pain. 2013, Feb 29(2): 162-171 (abstract).

Low dose vaporized cannabis significantly improves neuropathic pain.

Wilsey, Barth, et al.

Journal of Pain. 2013 Feb 14(2): 136-148.

Information for health care professionals. Cannabis (marihuana, marijuana) and cannabinoids.

Health Canada. February 2013 (see separate binder).

Marijuana: a primer.

Armentano, Paul

NORML. 29 Jan 2013.

Role of cannabinoids in pain management.

Russo, Ethan B, et al.

Comprehensive treatment of chronic pain by medical, interventional and integrative approaches.

Deer, T.R., et al. (eds.), American Academy of Pain Medicine 2013, 181-197.

Pregnancy, breast feeding, and marijuana: a review article.

Hill, Meg, et al.

Obstetrical And Gynecological Survey. 2013 68(10): 710-718.

The impact of marijuana use on glucose, insulin, and insulin resistance among US adults.

Penner, Elizabeth A, et al.

The American Journal of Medicine. 2013 126(7): 583-589.

Modulating the endocannabinoid system in human health and disease: successes and failures.

Pacher, Pál, et al.

Federation of European Biochemical Societies (FEBS) Journal. 2013 280(9): 1918-1943.

Critical appraisal of the potential use of cannabinoids in cancer management. 

Cridge BJ, et. al

Cancer Management Research. 2013 5:301–13.

2012

Medical marijuana: clearing away the smoke.

Grant, Igor, et al.

The Open Neurology Journal. 2012, 6: 18-25.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Leweke, F M, et al.

Translational Psychiatry.  2012 2 e94.

Cannabidivarin is anticonvulsant in mouse and rat.

Hill, A J, et al.

British Journal of Pharmacology. 2012 Dec, 167(8): 1629-1642.

Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

Takeda, Shuso, et al.

Toxicol.Lett. 2012 Nov.15 214(3): 314-319.

Cannabinoids: a new hope for breast cancer therapy?

Caffarel, M M, et al.

Cancer Treatment Reviews. 2012 Nov. 38(7): 911-918 (abstract).

Cannabis – from cultivar to chemovar.

Hazekamp A, Fischedick JT

Drug Testing and Analysis. 2012 Jul-Aug; 4(7-8): 660-7.

Evolution of the content of THC and other major cannabinoids in drug-type cuttings and seedlings during growth of plants.

De Backer, B, et al.

Journal of Forensic Sciences. 2012 July 57(4): 918-922 (abstract).

Cannabis – a valuable drug that deserves better treatment.

Mechoulam, Raphael

Mayo Clinic Proceedings. 2012 Feb, 87(2): 107-109.

Cannabinoid hyperemesis: a case series of 98 patients.

Simonetto, D A, et al.

Mayo Clinic Proceedings. 2012 Feb, 87(2): 114-119.

Blurred boundaries: the therapeutics and politics of medical marijuana.

Bostwick, Michael J

Mayo Clinic Proceedings. 2012 Feb, 87(2): 172-186.

Epigenetic regulation of fatty acid amide hydrolase in Alzheimer Disease.

D’Addario, Claudio, et al.

PLoS One. 2012, 7(6): e39186.

Aroma therapy.

Gardner, Fred

Medical Marijuana. 2012, 29-34.

Cannabidiol inhibits lung cancer cell invasion and metastasis.

Ramer, Robert, et al.

The FASEB Journal, 2012 Apr, 1235-1248.

Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from cannabis sativa, on inflammation-induced hypermotility in mice.

Izzo, Angelo, et al.

British Journal of Pharmacology. 2012 Jun, 166(4): 1444-1460.

Emerging clinical applications for cannabis and cannabinoids: a review of the recent scientific literature, 5th edition.

Armento, Paul, et al.

NORML Foundation. 2012 Mar 14.

Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey(NHANES) III.

Rajavashisth, Tripatith B, et al.

BMJ OPEN. 2012 2.

Naturally occurring anxiolytic substances from aromatic plants of genus citrus.

Pimenta, Flavia Cristina Fernandes, et al.

Journal of Medicinal Plants Research. 2012 Jan 23, 6(3): 342-347.

Association between marijuana exposure and pulmonary function over 20 years.

Pletcher, Mark J, et al.

JAMA. 2012 January 11 307(2): 173-181.

The role of cannabinoids in prostate cancer: basic science perspective and potential clinical applications.

Ramos, Juan A, et al.

Indian Journal of Urology. 2012 Jan, 28(1): 9-14.

Cannabidiol enhances anandamide signaling and alleviates psychotic symptomes of schizophrenia.

Leweka, F M, et al.

Translational Psychiatry. 2012, e94.β

2011

The endocannabinoid system and cancer: therapeutic implication.

Guindon, Josee, et al.

British Journal of Pharmacology. 2011, 163: 1447-1467.

Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement.

Esposito, Giuseppe, et al.

PloS ONE. 2011 6(12): e28668.

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

Russo, Ethan B.

British Journal of Pharmacology. 2011, 163: 1344-1364.

Importance of terpenes. 

Spaulding, Nathan

Cannabishealthnewsmagazine.com. 2011 Nov.

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion and metastasis.

 McAllister, Sean D, et al.

Breast Cancer Research and Treatment. 2011 August 129(1): 37-47.

Sympto-relieving and neuroprotective effects of ten phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease.

Garcia, C, et al.

British Journal of Pharmacology. 2011 Aug, 163(7): 1495-150.

Obesity and cannabis use: results from 2 representative national surveys.

Le Strat, Yann, et al.

American Journal of Epidemiology. 2011 Aug. 24.

Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy.

Shrivastava, Ashutosh, et al.

Molecular Cancer Therapeutics. 2011 July 10(7): 1161-1172.

Who are medical marijuana patients? Population characteristics from nine California assessment clinics.

Reinarman, Craig, et al.

Journal of Psychoactive Drugs. 2011, 43(2): 128-135 (abstract).

Booklets on cannabis and specific medical conditions.

Americans for Safe Access (ASA). 2011 Feb.

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.

Lynch, Mary E, et al

British Journal of Pharmacology. 2011 72(5): 735-744.

Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis Sativa.

Ruhaak, Lucia Renee, et al.

Biological and Pharmaceutical Bulletin. 2011 34(5): 774-778.

Anandamide exerts its antiproloferative actions on cholangiocarcinoma by activation of the GPR55 receptor.

Huang, Li, et al.

Laboratory Investigation. 2011 91: 1007-1017.

Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.

Lorente, M, et al.

Cell Death and Differentiation. 2011 18: 959-973.

2010

Cannabinoids and the gut: New developments and emerging concepts.

Izzo, Angelo A, et al.

Pharmacology & Therapeutics. 2010 126: 21-38 (abstract).

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in human Huntington’s disease.

Blázquez, Cristina, et al.

Brain.2010 October 7.

Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Morgan, Celia J A, et al.

Neuropsychopharmacology. 2010 Aug, 35(9): 1879-1885.

Cannabinoids reduce erbB2-driven breast cancer progression through akt inhibition.

Caffarel, María M, et al.

Molecular Cancer. 22 July 2010, 9 196.

Hypotensive activity of terpenes found in essential oils.

Menezes, Igor A C, et al.

Zeitschrift für Naturforschung.2010 June 65c: 562-566.

The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation pain in mice. 

Bolognini, Daniele, et al.

British Journal of Pharmacology. 2010 Jun, 160(3): 677-687.

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Bhattacharyya, Sagnik, et al.

Neuropsychopharmacology. 2010 Feb, 35(3): 764-774.

Review on clinical studies with cannabis and cannabinoids 2005-2009.

Hazekamp, Arno, et al.

Cannabinoids. 2010, 5 (special issue): 1-21.

Cannabidiol enhances the inhibitory effects of ?9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Marcu, Jahan, et al.

Molecular Cancer Therapeutics. 2010 January 9(1): 180-189.

Metabolic fingerprinting of cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug stardardization purposes.

Fischedick, Justin Thomas, et al.

Phytochemistry. 2010 71: 2058-2073.

Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis.

Wolf, Susanna A, et al.

Cell Communication and Signaling. 2010, 8: 12 (abstract).

Cannabinoids and the gut: new developments and emerging concepts.

Izzo, Angelo A, et al.

Pharmacology & Therapeutics. 2010, 126: 21-28.

2009

Cannabis Review.

Hazekamp, Arno.

Department of Plant Metabolomics, Leiden University, Leiden. The Netherlands. 2008-2009 (see separate binder).

Emerging strategies for exploiting cannabinoid receptor agonists as medicines.

Pertwee, Roger G, et al.

British Journal of Pharmacology. 2009 156: 397-411.

Smoking marijuana does not cause lung cancer, Tashkin reiterates to patients out of time.

Gardner, Fred.

O’Shaughnessy’s.  2009 Summer.

The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).

Fraser, G A.

CNS Neuroscience & Therapeutics. 2009 Winter, 15(1): 84-88 (abstract).

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

Ren, Yanhua, et al.

The Journal of Neuroscience. 2009 Nov 25, 29(47): 14764-14769.

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

Izzo, Angelo A, et al.

Trends in Pharmacological Sciences. 2009  30(10) (abstract).

Preventative and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation.

Rogerio, Alexandre P, et al.

British Journal of Pharmacology. 2009 Oct, 15(4): 1074-1087.

A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.

Liang, C, et al.

Cancer Prevention Research (Phila). 2009 Aug, 2(8): 756-768 (abstract).

Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma.

Oesch, Susanne, et al.

Molecular Cancer Therapeutics. July 2009; 8(7): 1838-1845.

2008

The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway.

DeMorrow, Sharon, et al.

American Journal of Physiological Gastrointestinal and Liver Physiology. 2008 Dec. 295(6):

G1150-G1168.

Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures- A short review.

Svízenská, Ivana, et al.

Pharmacology, Biochemistry and Behavior. 2008 90: 501-508.

Cannabis improves symptoms of ADHD.

Strohbeck-Kuehner, Peter, et al.

Cannabinoids. 2008, 3(1): 1-3.

Neuroprotective effects of cannabidiol in endotoxin-induced uvetis: critical role of p38 MAPK activation

El-Remessy, A B, et al.

Molecular Vision. 2008, 14: 2190-2203.

Antihyperalgesic effect of a cannabis sativa in a rat model of neuropathic pain: mechanisms involved.

Cormelli, F, et al.

Phytotherapeutic Research. 2008, 22(8): 1017-1024 (abstract).

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Zuardi, Antonio Waldo

Revista Brasileira de Psiquiatria. 2008, Sep, 30(3).

Cannabidiol, extracted from cannabis sativa selectively inhibits hypermotility in mice.

Capasso, R, et al.

British Journal of Pharmacology. 2008 May 12, 154(5): 1001-1008.

Cannabinoids in the management of difficult to treat pain.

Russo, Ethan B

Therapeutics and Clinical Risk Management. 2008, 4(1): 245-259.

Gut modulatory, blood pressure lowering, diuretic and sedative activities of cardamom.

Gilani, Anwarul Hassan, et al.

Journal of Ethnopharmacology. 2008 Feb 12, 115(3): 463-472 (abstract).

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin.

Pertwee, R G

British Journal of Pharmacology. 2008 Jan, 153(2): 199-215.

Influence on cannabis use on severity of hepatitis C disease.

Ishida, Julie H, et al.

Clinical Gastroenterology and Hepatology. 2008 Jan, 6(1): 69-75.

2007

Cannabidiol as a novel inhibitor of ld-1 gene expression in aggressive breast cancer cells.

McAllister, Sean D, et al.

Molecular Cancer Therapeutics. 2007 November 6(11): 2921-2927.

Human cannabinoid pharmacokinetics.

Huestis, Marilyn A, et al.

Chemistry & Biodiversity. 2007 August 4(8): 1770-1804.

Opposing actions of endocannabinoids on cholangiocarcinoma growth.

DeMorrow, Sharon, et al.

The Journal of Biological Chemistry. 2007 April 27, 282(17): 13098-13113.

Marijuana cuts lung cancer tumor growth in half, study shows.

American Association for Cancer Research

Sciencedaily.com. 2007 Apr 17.

The effect of the volatile oil from ginger rhizomes (zingiber officinale), it’s fractions and isolated compounds on the 5-HT3 receptor complex and the serotoninergic system of the rat ileum. 

Rivazi, A, et al.

Planta Medica. 2007 Apr, 73(4): 355-362 (abstract).

Cannabis in painful HIV-associated sensory neuropathy. A randomized placebo-controlled trial.

Abrams, D I, et al.

Neurology. 2007 68: 515-521.

Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea.

Hazekamp, Arno, et al.

Journal of Ethnopharmacology. 2007 113: 85-90.

Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have potential therapeutic values in the treatment of psoriasis.

Wilkinson, J D, et al.

Journal of Dermatological Science. 2007 Feb, 45(2): 87-92 (abstract).

Screening of antibacterial activities of twenty-one oxygenated monoterpenes.

Kotan, Recep, et al.

Zeitschrift fur Naturforschung.2007, 62c: 507-513 (abstract).

Sedative effect of monoterpene alcohols in mice: a preliminary screening.

de Sousa, Damiao Pergentino, et al.

Zeitschrift fur Naturforschung. 2007, 62c: 563-566 (abstract).

D-Limonene: safety and clinical applications

Sun, Jidong, et al.

Alternative Medicine Review. 2007, 12(3): 259-264.

Dosing medical marijuana: rational guidelines on trial in Washington State.

Sunil, K, et al.

Medscape General Medicine. 2007, 9(3) 52.

2006

Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study.

Hashibe, Mia, et al.

Cancer Epidemiology, Biomarkers & Prevention. 2006 October 15(10): 1829-1834.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

Russo, Ethan, et al.

Medical Hypothesis. 2006, 66: 234-246.

Unheated cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways.

Verhoeckx, Kitty C M, et al.

International Immunopharmacology. 2006 6: 656-665.

Endocannabinoid mechanisms of pain modulation.

Hohmann, Andrea G, et al.

The AAPS Journal. 2006 8(4): E693-E708.

A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis (cannador) for postoperative pain management.

Holdcroft, Antita, et al.

Anesthesiology. 2006, 104(5): 1040-1046 (abstract).

Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol.

Hazekamp, Arno, et al.

Journal of Pharmaceutical Sciences. 2006, 95(6): 1308-1317 (abstract).

Interaction between terpenes and penicillin on bacterial strains resistant to beta-lactam antibiotics.

Gallucci, N, et al.

Molecular Medicinal Chemistry. 2006, 10: 30-32.

History of cannabis as a medicine: a review.

Zuardi, Antonio Waldo

Revista Brasileira de Psiquiatria. 2006, 28(2): 153-157.

Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug.

Zuardi, A W, et al.

Brazilian Journal of Medical and Biological Research. 2006, 39(4): 421-429.

Delta-9 tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.

Shmist, Y A, et al.

Molecular Cell Biochemistry. 2006 Feb. (abstract).

Antitumor activity of plant cannabinoids emphasis on the effect of cannabidiol on human breast carcinoma.

Ligresti, Alessia, et al.

The Journal of Pharmacology and Experimental Therapeutics. 2006 318(3): 1375-1387.

Endocannabinoid mechanisms of pain modulation.

Hohmann, Andrea G, et al.

The AAPS Journal. 2006 Nov. 17 8(4): E693-708.

Peripheral cannabinoid receptor, CB2, regulates bone mass.

Ofek, Orr, et al.

Proceedings of the National Academy of Sciences. 2006 January 17 103(3): 696-701.

2005

Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Thomas, Adele, et al.

British Journal of Pharmacology. 2005 Dec, 146(7): 917-926.

?-9-Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.

McKallip, Robert J, et al.

Journal of Immunology. 2005 174: 3281-3289.

Immunomodulatory and therapeutic properties of the Nigella sativa L. seed.

Salem, Mohammed Labib

International Immunopharmacology. 2005, 5: 1749-1770 (abstract).

Involvement of cannabinoids in cellular proliferation.

Lopez-Rodriguez, Maria L, et al.

Mini-Reviews in Medicinal Chemistry. 2005, 5: 97-106 (abstract).

Antileishmanial activity of the terpene nerolidol.

Arruda, Denise C, et al.

Antimicrobial Agents and Chemotherapy, 2005, 49(5): 1679-1687.

Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.

Ständer, S, et al.

Journal of Dermatological Science. 2005 June 38(3): 177-188.

Chemical constituents of marijuana: the complex mixture of natural cannabinoids.

ElSohly, Mahmoud A, et al.

Life Sciences. 2005 78: 539-548.

2004

Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms.

Venderova, Katerina, et al.

Movement Disorders. 2004 Sep, 19(9): 1102-1106 (abstract).

Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpes viruses in vitro.

Medveczky, Peter G, et al.

BMC Medicine. 2004 2: 34

Cannabis, cannabinoids and reproduction.

Park, Boram, et al.

Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004, 70: 189-197.

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic.

Giuffrida, Andrea, et al.

Neuropsychopharmacology. 2004 29: 2108-2114.

Cannabis for dyskinesia in Parkinson’s disease. A randomized double-blind crossover study.

Carroll, C B, et al.

Neurology. 2004 Oct 12, 63(7): 1245-1250 (abstract).

Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss.

Avraham, Y, et al.

Pharmacology Biochemistry and Behavior. 2004 Apr, 77(4): 675-684 (abstract).

Medicinal cannabis: rational guidelines for dosing.

Carter, Gregory T, et al.

Drugs.2004 May 7(5): 464-470.

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Russo, E B

Neuroendocrinology Letters. 2004 Feb-Apr, 25(1-2): 31-39 (abstract).

Chronic conditions treated with cannabis. Encountered between 1990-2004. “Dr. Tod’s List.”

Mikuriya, Tod.

2004.

Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action.

Narishetty, Sunil Thomas Kumar, et al.

Journal of Controlled Release. 2004 Mar 24, 95(3): 367-379 (abstract).

2003

The therapeutic potential of cannabis.

Baker, David, et al.

The Lancet Neurology. 2003 May, 2(5): 291-298 (abstract).

Non-acute (residual) neurocognitive effects of cannabis use: A meta-analytic study.

Grant, Igor, et al.

Journal of the International Neuropsychological Society. 2003 9: 679-689.

Cannabinoids and the gut.

Vigna, Steven R,.

Gastroenterology. 2003 Sept. 125: 973-975 (editorial).

Possible endocannabinoid control of colorectal cancer growth.

Ligresti, Alessia et al.

Gastroenterology. 2003 Sept. 125: 677-687.

Cannabis and ADD.

Bearman, David

http://www.davidbearman.com. 2003.

Cannabis and the brain.

Iversen, Leslie

Brain. 2003, 126: 1252-1270.

Guidelines for cultivating cannabis for medicinal purposes.

Scholten, Willem K

Journal of Cannabis Therapeutics. 2003, 3(2): 51-61.

The inheritance of chemical phenotype in cannabis satival L.

Meijer, Etienne P M de

Genetics. 2003 Jan 1, 163(1): 335-346.

An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice.

Izzo, Angelo A, et al.

Gastroenterolology. 2003 Sept. 125: 765-774.

2002

The endogenous cannabinoid system controls extinction of aversive memories

Giovanni M, et.al

Nature. 418, 530-534 (2002).

A cDna clone for β-caryophyllene synthase from Artemisia annua.

Cai, Yu, et al.

Phytochemistry. 2002 Nov, 61(5): 523-529 (abstract).

Chronic cannabis use in the compassionate investigational new drug program:

an examination of benefits and adverse effects of legal cannabis.

Russo, Ethan, et al.

Journal of Cannabis Therapeutics. 2002 2(1): 3-57.

2001

Pharmacological actions and therapeutic uses of cannabis and cannabinoids.

Kumar, R N, et al.

Anaesthesia. 2001 Nov, 56(11): 1059-1068 (abstract).

Cannabis and cannabis extracts: greater than the sum of their parts?

McPartland, John, et al.

Hayworth Press. 2001.

2000 – 1843

Cannabinoids in clinical practice.

Williamson, Elizabeth, et al.

Drugs. 2000 Dec, 60(6): 1303-1314 (abstract).

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.

Malfait, A M, et al.

Proceedings of the National Academy of Sciences. 2000, 97(17): 9561-9566.

Prevention and therapy of cancer by dietary monoterpenes.

Crowell, Pamela L

Journal of Nutrition. 1999, 129(3): 775s-778s.

The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.

De Petrocellis, Luciano, et al.

Proceedings of the National Academy of Sciences USA. 1998 July 95: 8375-8380.

An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity.

Ben-Shabat, Shimon, et al.

European Journal of Pharmacology. 1998 353: 23-31 (abstract).

Essential oil of cannabis sativa L. strains.

Mediavilla, Vito, et al.

Journal of the International Hemp Association. 1997, 4(2): 82-85.

Geraniol, an inhibitor of mevalonate biosynthesis, suppresses the growth of hepatomas and melanomas transplanted to rats and mice.

Yu, Suzanne G, et al.

Journal of Nutrition. 1995, 125(11): 2763-2767 (abstract).

Chemical ecology of cannabis.

Pate, David W

Journal of the International Hemp Association. 1994, 2: 29, 32-37.

Action of cannabidiol on the anxiety and others effects produced by ?9-thc in normal subjects.

Zuardi, A W, et al.

Psychopharmacology. 1982 76: 245-250 (abstract).

Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice.

Karler, Ralph

British Journal of Pharmacology. 1980 Mar, 68(3): 479-484.

On the preparation of the Indian hemp or gunjah.

O’Shaughnessy, W B, et al.

Provincial Medical Journal. 1843, no. 123: 363-369.